Abivax's 25mg Obefazimod: A Promising Ulcerative Colitis Treatment

Abivax, a clinical-stage biotechnology company, has reported positive interim efficacy and safety analysis of once-daily 25mg obefazimod in moderate to severe ulcerative colitis (UC) patients after two years of open-label maintenance. This is a significant milestone in the development of a novel treatment for UC, a chronic inflammatory disease that affects millions worldwide.

The 25mg dose of obefazimod demonstrated maintenance of clinical remission at weeks 48 and 96, with efficacy and safety profiles consistent with previous studies. The treatment was well-tolerated, with a safety profile consistent with prior studies and no new safety signals detected. Patient retention rates were high, with only 12% (16/130) of patients discontinuing in the first year and 5% (6/114) discontinuing during the second year of treatment.


Obefazimod's potential lies in its ability to enhance the expression of a single microRNA, miR-124, which has been shown to potentially stabilize the immune response in patients with chronic inflammatory diseases. Phase 2 clinical trials in patients with UC have generated positive data, resulting in the initiation of a pivotal global Phase 3 clinical trial program (ABTECT Program).


The long-term impact of obefazimod on patient quality of life and disease progression is promising. The maintenance of clinical remission and the promising tolerability data observed to date underscore the potential of obefazimod as a treatment for ulcerative colitis. The Company looks forward to presenting this data at an upcoming medical meeting.

In conclusion, Abivax's 25mg obefazimod has shown encouraging results in the treatment of moderate to severe ulcerative colitis. With a well-tolerated safety profile and the potential to maintain long-term efficacy, obefazimod could become a valuable addition to the UC treatment landscape. As the global Phase 3 clinical trial program progresses, further data will be crucial in evaluating the full potential of this novel therapy.